![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 17alpha-ethynylestradiol | multiple interactions | EXP | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of LOXL3 mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of LOXL3 mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of LOXL3 mRNA | CTD | PMID:27562557 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of LOXL3 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1322239 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of LOXL3 mRNA | CTD | PMID:20106945, PMID:21632981 | 3,4-methylenedioxymethamphetamine | increases expression | EXP | | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of LOXL3 mRNA | CTD | PMID:20188158 | acetamide | increases expression | ISO | RGD:1311011 | 6480464 | acetamide results in increased expression of LOXL3 mRNA | CTD | PMID:31881176 | acrylamide | increases expression | ISO | RGD:1311011 | 6480464 | Acrylamide results in increased expression of LOXL3 mRNA | CTD | PMID:28959563 | arsenite(3-) | decreases expression | EXP | | 6480464 | arsenite results in decreased expression of LOXL3 mRNA | CTD | PMID:18929588 | arsenite(3-) | affects expression | ISO | RGD:1322239 | 6480464 | arsenite affects the expression of LOXL3 mRNA | CTD | PMID:22959463 | arsenite(3-) | multiple interactions | EXP | | 6480464 | TRP53 protein affects the reaction [arsenite results in decreased expression of LOXL3 mRNA] | CTD | PMID:18929588 | atrazine | increases expression | ISO | RGD:1322239 | 6480464 | Atrazine results in increased expression of LOXL3 mRNA | CTD | PMID:22378314 | benzo[a]pyrene | increases methylation | ISO | RGD:1322239 | 6480464 | Benzoapyrene results in increased methylation of LOXL3 promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases methylation | ISO | RGD:1322239 | 6480464 | Benzoapyrene results in decreased methylation of LOXL3 5' UTR | CTD | PMID:27901495 | benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzoapyrene results in increased expression of LOXL3 mRNA | CTD | PMID:32417428 | bisphenol A | decreases expression | ISO | RGD:1311011 | 6480464 | bisphenol A results in decreased expression of LOXL3 mRNA | CTD | PMID:25181051, PMID:30816183 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of LOXL3 mRNA | CTD | PMID:29161229 | bisphenol A | increases methylation | ISO | RGD:1311011 | 6480464 | bisphenol A results in increased methylation of LOXL3 gene | CTD | PMID:28505145 | carbamazepine | affects expression | ISO | RGD:1322239 | 6480464 | Carbamazepine affects the expression of LOXL3 mRNA | CTD | PMID:25979313 | carbon nanotube | decreases expression | EXP | | 6480464 | Nanotubes, Carbon results in decreased expression of LOXL3 mRNA | CTD | PMID:25926378 | chromium(6+) | increases expression | ISO | RGD:1322239 | 6480464 | chromium hexavalent ion results in increased expression of LOXL3 protein | CTD | PMID:28596144 | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with RELB mutant form co-treated with TNF protein] results in decreased expression of LOXL3 mRNA | CTD | PMID:23625948 | deoxynivalenol | decreases expression | ISO | RGD:1322239 | 6480464 | deoxynivalenol results in decreased expression of LOXL3 mRNA | CTD | PMID:31863870 | dexamethasone | decreases expression | ISO | RGD:1322239 | 6480464 | Dexamethasone results in decreased expression of LOXL3 mRNA | CTD | PMID:25047013 | diethylstilbestrol | increases expression | ISO | RGD:1311011 | 6480464 | Diethylstilbestrol results in increased expression of LOXL3 mRNA | CTD | PMID:21658437 | diuron | decreases expression | ISO | RGD:1311011 | 6480464 | Diuron results in decreased expression of LOXL3 mRNA | CTD | PMID:25152437 | ethanol | increases expression | EXP | | 6480464 | Ethanol results in increased expression of LOXL3 mRNA | CTD | PMID:30319688 | furan | increases methylation | ISO | RGD:1311011 | 6480464 | furan results in increased methylation of LOXL3 gene | CTD | PMID:22079235 | furan | increases expression | ISO | RGD:1311011 | 6480464 | furan results in increased expression of LOXL3 mRNA | CTD | PMID:27387713 | hypochlorous acid | decreases expression | EXP | | 6480464 | Hypochlorous Acid results in decreased expression of LOXL3 mRNA | CTD | PMID:19376150 | irinotecan | decreases expression | ISO | RGD:1322239 | 6480464 | Irinotecan analog results in decreased expression of LOXL3 mRNA | CTD | PMID:18927307 | lead diacetate | decreases expression | EXP | | 6480464 | lead acetate results in decreased expression of LOXL3 mRNA | CTD | PMID:22609695 | oxaliplatin | multiple interactions | ISO | RGD:1311011 | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of LOXL3 mRNA | CTD | PMID:25729387 | silicon dioxide | increases expression | ISO | RGD:1322239 | 6480464 | Silicon Dioxide analog results in increased expression of LOXL3 mRNA | CTD | PMID:25895662 | silver atom | increases expression | EXP | | 6480464 | Silver results in increased expression of LOXL3 mRNA | CTD | PMID:27131904 | silver(0) | increases expression | EXP | | 6480464 | Silver results in increased expression of LOXL3 mRNA | CTD | PMID:27131904 | sunitinib | decreases expression | ISO | RGD:1322239 | 6480464 | Sunitinib results in decreased expression of LOXL3 mRNA | CTD | PMID:31533062 | topotecan | increases expression | ISO | RGD:1311011 | 6480464 | Topotecan results in increased expression of LOXL3 mRNA | CTD | PMID:25729387 | topotecan | multiple interactions | ISO | RGD:1311011 | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of LOXL3 mRNA | CTD | PMID:25729387 | tris(2-butoxyethyl) phosphate | affects expression | ISO | RGD:1322239 | 6480464 | tris2-butoxyethyl phosphate affects the expression of LOXL3 mRNA | CTD | PMID:29024780 | tunicamycin | decreases expression | ISO | RGD:1322239 | 6480464 | Tunicamycin results in decreased expression of LOXL3 mRNA | CTD | PMID:22378314 | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of LOXL3 mRNA | CTD | PMID:17292431 | valproic acid | increases expression | ISO | RGD:1322239 | 6480464 | Valproic Acid results in increased expression of LOXL3 mRNA | CTD | PMID:23179753 | valproic acid | affects expression | ISO | RGD:1322239 | 6480464 | Valproic Acid affects the expression of LOXL3 mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:1322239 | 6480464 | Valproic Acid results in decreased expression of LOXL3 mRNA | CTD | PMID:28001369 | |